153 related articles for article (PubMed ID: 29657990)
1. Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy.
Linge A; Löck S; Krenn C; Appold S; Lohaus F; Nowak A; Gudziol V; Baretton GB; Buchholz F; Baumann M; Krause M
Clin Transl Radiat Oncol; 2016 Dec; 1():19-26. PubMed ID: 29657990
[TBL] [Abstract][Full Text] [Related]
2. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
[TBL] [Abstract][Full Text] [Related]
3. Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy.
Linge A; Schmidt S; Lohaus F; Krenn C; Bandurska-Luque A; Platzek I; von Neubeck C; Appold S; Nowak A; Gudziol V; Buchholz F; Baretton GB; Baumann M; Löck S; Krause M
Clin Transl Radiat Oncol; 2019 May; 16():40-47. PubMed ID: 30993218
[TBL] [Abstract][Full Text] [Related]
4. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Löck S; Linge A; Lohaus F; Ebert N; Gudziol V; Nowak A; Tinhofer I; Kalinauskaite G; Guberina M; Stuschke M; Balermpas P; von der Grün J; Grosu AL; Debus J; Ganswindt U; Belka C; Peeken JC; Combs SE; De-Colle C; Zips D; Baretton GB; Krause M; Baumann M;
Radiother Oncol; 2022 Apr; 169():8-14. PubMed ID: 35182686
[TBL] [Abstract][Full Text] [Related]
5. Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG.
Linge A; Löck S; Gudziol V; Nowak A; Lohaus F; von Neubeck C; Jütz M; Abdollahi A; Debus J; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Bayer C; Belka C; Pigorsch S; Combs SE; Welz S; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Baumann M; Krause M;
Clin Cancer Res; 2016 Jun; 22(11):2639-49. PubMed ID: 26755529
[TBL] [Abstract][Full Text] [Related]
6. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Lohaus F; Linge A; Tinhofer I; Budach V; Gkika E; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; von Neubeck C; Baretton GB; Löck S; Thames HD; Krause M; Baumann M;
Radiother Oncol; 2014 Dec; 113(3):317-23. PubMed ID: 25480095
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
Patil S; Linge A; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S;
Radiother Oncol; 2022 Jun; 171():91-100. PubMed ID: 35429503
[TBL] [Abstract][Full Text] [Related]
8. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
[TBL] [Abstract][Full Text] [Related]
9. Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
Patil S; Tawk B; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S; Linge A;
Radiother Oncol; 2022 Feb; 167():300-307. PubMed ID: 34999136
[TBL] [Abstract][Full Text] [Related]
10. SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy.
De-Colle C; Mönnich D; Welz S; Boeke S; Sipos B; Fend F; Mauz PS; Tinhofer I; Budach V; Jawad JA; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Bayer C; Belka C; Pigorsch S; Combs SE; Lohaus F; Linge A; Krause M; Baumann M; Zips D; Menegakis A
Clin Transl Radiat Oncol; 2017 Aug; 5():28-36. PubMed ID: 29594214
[TBL] [Abstract][Full Text] [Related]
11. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
Linge A; Patil S; Grosser M; Lohaus F; Gurtner K; Kemper M; Gudziol V; Haim D; Nowak A; Tinhofer I; Zips D; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Gani C; Jöhrens K; Baretton GB; Löck S; Baumann M; Krause M;
Radiother Oncol; 2024 Feb; 191():110055. PubMed ID: 38109944
[TBL] [Abstract][Full Text] [Related]
12. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
13. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).
Balermpas P; Rödel F; Rödel C; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Gkika E; Stuschke M; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Stangl S; Belka C; Pigorsch S; Multhoff G; Combs SE; Mönnich D; Zips D; Fokas E
Int J Cancer; 2016 Jan; 138(1):171-81. PubMed ID: 26178914
[TBL] [Abstract][Full Text] [Related]
14. Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation.
van der Heijden M; Essers PBM; de Jong MC; de Roest RH; Sanduleanu S; Verhagen CVM; Hamming-Vrieze O; Hoebers F; Lambin P; Bartelink H; Leemans CR; Verheij M; Brakenhoff RH; van den Brekel MWM; Vens C
Front Oncol; 2019; 9():1470. PubMed ID: 31998639
[No Abstract] [Full Text] [Related]
15. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
Linge A; Schötz U; Löck S; Lohaus F; von Neubeck C; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Bunea H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Lauber K; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Krause M; Belka C; Baumann M;
Radiother Oncol; 2018 Apr; 127(1):27-35. PubMed ID: 29295747
[TBL] [Abstract][Full Text] [Related]
16. Association between cancer stem cell gene expression signatures and prognosis in head and neck squamous cell carcinoma.
Kim SI; Woo SR; Noh JK; Lee MK; Lee YC; Lee JW; Kong M; Ko SG; Eun YG
BMC Cancer; 2022 Oct; 22(1):1077. PubMed ID: 36261806
[TBL] [Abstract][Full Text] [Related]
17. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
18. Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC.
Jakob M; Sharaf K; Schirmer M; Leu M; Küffer S; Bertlich M; Ihler F; Haubner F; Canis M; Kitz J
Strahlenther Onkol; 2021 Mar; 197(3):231-245. PubMed ID: 32588101
[TBL] [Abstract][Full Text] [Related]
19. DNA-Methylome-Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy.
Tawk B; Rein K; Schwager C; Knoll M; Wirkner U; Hörner-Rieber J; Liermann J; Kurth I; Balermpas P; Rödel C; Linge A; Löck S; Lohaus F; Tinhofer I; Krause M; Stuschke M; Grosu AL; Zips D; Combs SE; Belka C; Stenzinger A; Herold-Mende C; Baumann M; Schirmacher P; Debus J; Abdollahi A
Clin Cancer Res; 2023 Aug; 29(16):3051-3064. PubMed ID: 37058257
[TBL] [Abstract][Full Text] [Related]
20. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.
Hess J; Unger K; Maihoefer C; Schüttrumpf L; Wintergerst L; Heider T; Weber P; Marschner S; Braselmann H; Samaga D; Kuger S; Pflugradt U; Baumeister P; Walch A; Woischke C; Kirchner T; Werner M; Werner K; Baumann M; Budach V; Combs SE; Debus J; Grosu AL; Krause M; Linge A; Rödel C; Stuschke M; Zips D; Zitzelsberger H; Ganswindt U; Henke M; Belka C
Clin Cancer Res; 2019 Mar; 25(5):1505-1516. PubMed ID: 30171046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
